BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.
BMRN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Biomarin Pharmaceutical Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biomarin Pharmaceutical Inc ranked in the 99th percentile in terms of potential gain offered. As the table below shows, the model suggests the stock is dramatically undervalued -- investors should note, though, that such returns are always unlikely and not to be expected. As for the metrics that stood out in our discounted cash flow analysis of Biomarin Pharmaceutical Inc, consider:
Its compound free cash flow growth rate, as measured over the past 0.25 years, is 4.87% -- higher than 97.54% of stocks in our DCF forecasting set.
The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.28% of the free cash flow producing stocks we're observing.
As a business, Biomarin Pharmaceutical Inc experienced a tax rate of about 102% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 93.88% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BMRN, try KMDA, NVAX, THC, VRTX, and GEN.
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the…
LOS ANGELES--(BUSINESS WIRE)---- $BMRN #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020 (the “Class Period”). BioMarin investors have until November 24, 2020 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to participate. On A
NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of…
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States Distric
Akero Therapeutics to continue with Mid stage Efruxifermin trial Akero Therapeutics Inc. (AKRO) reported that the company has received a written guidance from the FDA, allowing the company to pursue a novel combined Phase 2b/3 study design for pivotal efruxifermin ((EFX)) trials in NASH patients. The proposed trial design entails...
Avisol Capital Partners on Seeking Alpha | September 29, 2020